Cencora Inc.
$ 364.38
-0.45%
24 Feb - close price
- Market Cap 71,204,069,000 USD
- Current Price $ 364.38
- High / Low $ 367.63 / 360.97
- Stock P/E 43.84
- Book Value 9.81
- EPS 8.35
- Next Earning Report 2026-05-06
- Dividend Per Share $2.25
- Dividend Yield 0.62 %
- Next Dividend Date 2026-03-02
- ROA 0.03 %
- ROE 1.34 %
- 52 Week High 376.89
- 52 Week Low 246.34
About
CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.
Analyst Target Price
$403.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-05 | 2024-11-06 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-02 | 2023-08-02 | 2023-05-02 |
| Reported EPS | 2.87 | 3.84 | 4 | 4.42 | 3.73 | 3.34 | 3.34 | 3.8 | 3.28 | 2.86 | 2.92 | 3.5 |
| Estimated EPS | 3.39 | 3.79 | 3.84 | 4.1 | 3.52 | 3.22 | 3.22 | 3.69 | 2.89 | 2.81 | 2.83 | 3.3 |
| Surprise | -0.52 | 0.05 | 0.16 | 0.32 | 0.21 | 0.12 | 0.12 | 0.11 | 0.39 | 0.05 | 0.09 | 0.2 |
| Surprise Percentage | -15.3392% | 1.3193% | 4.1667% | 7.8049% | 5.9659% | 3.7267% | 3.7267% | 2.981% | 13.4948% | 1.7794% | 3.1802% | 6.0606% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 4.75 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-02 | 2025-12-01 | 2025-09-03 | 2025-06-02 | 2025-03-03 | 2024-11-29 | 2024-08-26 | 2024-05-24 | 2024-02-26 | 2023-11-27 |
| Amount | $0.6 | $0.6 | $0.55 | $0.55 | $0.55 | $0.55 | $0.51 | $0.51 | $0.51 | $0.51 |
Next Dividend Records
| Dividend per share (year): | $2.25 |
| Dividend Yield | 0.62% |
| Next Dividend Date | 2026-03-02 |
| Ex-Dividend Date | 2026-02-13 |
Recent News: COR
2026-02-24 11:49:51
Cardinal Health's 2026 Biosimilars Report indicates that biosimilar drugs have generated over $56 billion in U.S. healthcare savings since 2015 and could save up to $181 billion more if market conditions become favorable. The report also highlights high provider confidence, with 99% of surveyed physicians comfortable explaining biosimilars, and notes that oncology biosimilars achieve an 81% market share within five years. Consistent reimbursement is identified as a critical factor for sustained adoption, with nearly 25 new biosimilars expected to receive FDA approval in the next two years.
2026-02-24 08:49:55
Cencora (COR) shares recently closed at US$366.03, prompting a re-evaluation of its valuation metrics against recent performance. Despite trading near its recent highs, a narrative suggests Cencora is 8.4% undervalued with a fair value of US$399.80, driven by its investment in digital infrastructure. However, its P/E ratio of 43.8x is significantly higher than industry averages, indicating less room for error.
2026-02-24 05:13:55
A law firm has initiated an investigation into McKesson's Board regarding potential fiduciary breaches related to its 2013 Stock Plan and a recommendation to issue 30 million additional shares. This probe raises investor concerns about ownership dilution, future earnings per share, and the company's capital allocation strategies, contrasting with its ongoing share repurchase activities. Despite these governance questions, the article notes that the core investment narrative, driven by prescription growth and efficiency, remains largely unaffected in the near term.
2026-02-22 08:23:04
Cardinal Health Inc. plays a crucial, often unseen, role in the US healthcare system by distributing prescription drugs and medical products to pharmacies and hospitals. While not a "hype" stock, its strategic shifts, stability, and dividend make it attractive to long-term, risk-aware investors looking for healthcare exposure. The company's recent focus on cleaning up opioid litigation and improving its medical segment has drawn renewed attention from analysts and financial media.
2026-02-20 22:45:20
This article provides a risk analysis for the Cencora, Inc. 5.65% 13-FEB-2056 bond, identified by the ISIN US3073EBF1 and traded on the Dusseldorf Stock Exchange. It highlights key metrics for assessing credit risk, inflation protection, and the issuer's rating to help users make informed decisions. The platform also offers access to exclusive analyst ratings for bonds.
2026-02-19 15:45:22
Cencora (COR) recently issued $3 billion in long-term notes to refinance short-term debt related to its OneOncology acquisition, improving its balance sheet and reducing refinancing risk. This move solidifies Cencora's investment narrative, which hinges on its pharmaceutical distribution scale and expanding specialty services offsetting margin pressures. While the refinancing provides more financial flexibility, investors should continue to monitor potential challenges from generics and biosimilars.
